Trading was light with 134K shares changing hands in the last trading session. Overall, volume was down 84.88% under the stocks normal daily volume.
Traders are more bearish on MYOS RENS Technology Inc. if you look at the uptick in short interest. The firm saw a rise in short interest from September 29, 2017 to October 13, 2017 of 1.06%. Short interest increased from 415,550 to 419,935 over that timeframe. Days to cover increased from 4.0 to 5.0 and the short interest percentage is 0.07% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (MYOS). As of the end of the quarter Ubs Group Ag had sold 322 shares trimming its holdings by 64.4%. The value of the company’s investment in MYOS RENS Technology Inc. went from $1,000 to $1,000 decreasing 0.0% quarter over quarter. As of quarter end Vanguard Group Inc had disposed of a total of 16,215 shares trimming its stake by 99.4%. The value in dollars decreased from $47,000 to $0 a change of $47,000 since the last quarter.
As of quarter end Deutsche Bank Ag had acquired a total of 100 shares growing its position 25.0%. The value of the investment in (MYOS) decreased from $1,000 to $0 a change of 100.0% for the reporting period. Morgan Stanley cut its ownership by shedding 2,765 shares a decrease of 34.6% from 03/31/2017 to 06/30/2017. Morgan Stanley currently owns 5,235 shares with a value of $10,000. The value of the position overall is down by 56.5%.
The company is up by 3.62% percent from yesterday’s close. The stock last traded at $1.32 just a bit lower than $1.41, the stock’s 50 day moving average and which is significantly lower than the 200 day moving average of $1.77. The 50 day moving average was down $-0.09 whereas the 200 day moving average was down $-0.46 or -25.724%.
MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, launched on April 11, 2007, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focusing on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. The Company is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin..